Monmouth Junction, NJ, United States of America

Zhi-Cai Shi

This inventor holds 27 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Lexicon Pharmaceuticals, Inc., Merck Sharp + Dohme Corp., Lexicon Genetics Corporation. Active years: 2003-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhi-Cai Shi. Retrieved from https://idiyas.com/inventor/zhi-cai-shi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 5)

% Patents Active = 88.9

CIPO Patents = 4

EPO Patents = 18 (Patent Applications = 23)

Average Co-Inventor Count = 6.4

ph-index = 6

Forward Citations = 90(Granted Patents)

Location History:

North Brunswick, NJ (US) (2003 - 2004)
South Brunswick, NJ (US) (2005)
Monmouth Junction, NJ (US) (2007 - 2021)

Company Filing History:

13 out of 89

Lexicon Pharmaceuticals, Inc.

patents

12 out of 2,405

Merck Sharp + Dohme Corp.

patents

1 out of 102

Lexicon Genetics Corporation

patents

4. 1 out of 834,570

Other

patents

Years Active: 2003-2021

Loading Chart...

Areas of Expertise:

IDO Inhibitors

Insulin Receptor Agonists

Potassium Channel Inhibitors

Prolylcarboxypeptidase Inhibitors

Tryptophan Hydroxylase Inhibitors

Amino Acid Derivatives

Thiazolopyrazoles

Diabetes Treatment

Nucleophilic Substitution

Carboxylic Acids

Phenylalanines

Spiropiperidine Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10988487 - Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-04-27),

2. 10800827 - Insulin receptor partial agonists (2020-10-13),

3. 10183981 - Insulin receptor partial agonists (2019-01-22),

4. 10017556 - Insulin receptor partial agonists (2018-07-10),

5. 9951052 - Inhibitors of the renal outer medullary potassium channel (2018-04-24),

6. 9777002 - Inhibitors of the renal outer medullary potassium channel (2017-10-03),

7. 9527830 - Inhibitors of the renal outer medullary potassium channel (2016-12-27),

8. 9493474 - Inhibitors of the renal outer medullary potassium channel (2016-11-15),

9. 9365539 - Prolylcarboxypeptidase inhibitors (2016-06-14),

10. 9139585 - Inhibitors of the Renal Outer Medullary Potassium channel (2015-09-22),

11. 9108947 - Inhibitors of the Renal Outer Medullary Potassium channel (2015-08-18),

12. 8785634 - Spiropiperidine prolylcarboxypeptidase inhibitors (2014-07-22),

13. 8772482 - 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use (2014-07-08),

14. 8629156 - Tryptophan hydroxylase inhibitors (2014-01-14),

15. 8569299 - Prolylcarboxypeptidase inhibitors (2013-10-29),

Title: The Inventor Extraordinaire: Zhi-Cai Shi

Introduction: Zhi-Cai Shi, a trailblazing inventor based in Monmouth Junction, NJ, has truly made his mark in the world of patents with a remarkable tally of 27 groundbreaking innovations.

Latest Patents: Among his recent patents, one notable creation is the Substituted nʹ-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors. These compounds pave the way for potential treatments of IDO-associated diseases and disorders. Additionally, Zhi-Cai Shi's Insulin receptor partial agonists, including insulin dimers and analogs, offer new possibilities for partial agonist therapy at the insulin receptor.

Career Highlights: Zhi-Cai Shi has lent his inventive genius to companies like Lexicon Pharmaceuticals, Inc., and Merck Sharp & Dohme Corporation. His relentless pursuit of innovation has led to numerous patents that have the potential to revolutionize the healthcare industry.

Collaborations: Throughout his career, Zhi-Cai Shi has collaborated with esteemed colleagues such as Haihong Jin and Ashok R Tunoori. Together, they have worked tirelessly to push the boundaries of scientific innovation.

Conclusion: Zhi-Cai Shi's dedication to innovation and his impressive portfolio of patents are a testament to his unwavering commitment to advancing the field of pharmaceuticals. His inventive spirit, coupled with his collaborations and career milestones, solidify his position as a pioneering inventor in the realm of healthcare innovations.

Profile summary based on public USPTO records.